Capecitabine
Pancreatic Neuroendocrine Tumor
Gustave Roussy, Cancer Campus, Grand ParisSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
32 Active assets in the Pancreatic Neuroendocrine Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxodotreotide University of Chicago | Phase 4 | BBB |
Everolimus Exelixis | Phase 4 | BBB |
Irinotecan M.D. Anderson Cancer Center | Phase 2/3 | BB |
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- RayzeBio, Inc. | Phase 3 | BB |
Zanzalintinib Exelixis | Phase 3 | BB |
View all 49 →
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →